Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. gliomark

GLIOMARK SIGNED

Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 GLIOMARK project word cloud

Explore the words cloud of the GLIOMARK project. It provides you a very rough idea of what is the project "GLIOMARK" about.

grade    gliomas    designation    spect    tolerated    resonance    reproducibility    greek    emission    guarantee    objective    leader    barrier    clinically    sme    preparation    diagnostic    containing    biomarker    vivo    latter    orphan    therapies    first    innovative    niche    diagnose    handling    detect    affordable    market    reconstituted    global    grading    yield    gliotect    specificity    fast    pertechnetate    gliomark    computer    chemical    radiotracer    approval    permeability    outcome    rare    lifted    sensitivity    speciality    ttf    mography    expensive    tomography    point    blood    imaging    kit    glioma    aggregated    subsequent    diagnosis    aggressiveness    tlr    selling    reliably    hence    proactina    single    diagnostics    disease    biopsies    poor    tetrofosmin    hospitals    invasive    differential    magnetic    safe    confirmation    reliability    tumor    sale    replace    validate    brain    99mtc    prognosis    technique    combination    exclude    bbb    opportunity    validated    accomplished    instructions    assesses    unable    photon    distinguish    exclusivity    diseases   

Project "GLIOMARK" data sheet

The following table provides information about the project.

Coordinator		 CONSULTECH TECHNOLOGIEBERATUNG GMBH 

Organization address
address: MORGENSTERNSTRASSE 24
city: BERLIN
postcode: 12207
website: www.consultech.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.gliomark.eu
 Total cost 4˙705˙344 €
 EC max contribution 4˙705˙344 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSULTECH TECHNOLOGIEBERATUNG GMBH DE (BERLIN) coordinator 3˙167˙094.00
2    PRO-ACTINA CHIMIKI TECHNOLOGIA ANONIMI ETAIRIA EL (MAROUSI ATHENS) participant 1˙538˙250.00

Map

 Project objective

Objective of GLIOMARK is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis and grading of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer To-mography (SPECT). The outcome of GLIOMARK is GlioTect, a diagnostic kit containing handling/diagnostic instructions and tetrofosmin. The latter has to be reconstituted with 99mTc pertechnetate to yield TTF, which will be used in combination with SPECT. Often computer tomography or magnetic resonance imaging are unable to detect low-grade gliomas or distinguish glioma from other diseases. Hence, brain biopsies are necessary for confirmation of diagnosis and grading of gliomas. GlioTect with TTF/SPECT enables reliable, fast differential diagnosis and grading of gliomas as non-invasive method. This has an immediate impact on the type and aggressiveness of subsequent therapies. Gliomas are recognized as a rare tumor disease with poor prognosis and orphan diagnostic designation for GlioTect will guarantee 10 years of market exclusivity upon approval. ProActina, a Greek chemical-speciality SME having identified this innovative niche market opportunity could become global market leader in glioma diagnostics. Development is at TLR level 6-7 and will be lifted to 9. Expected market application is the sale of GlioTect for preparation of TTF for use with SPECT. End users are hospitals that use the kit to reliably diagnose or exclude gliomas without the need for expensive equipment. Taken together, the aggregated unique selling point of SPECT in combination with TTF (generated by means of GlioTect) is the first ever and only glioma diagnostic, which assesses a clinically validated glioma biomarker, has high reliability, reproducibility, sensitivity, as well as specificity, which is used to replace an invasive method, is safe, well tolerated, widely available and more affordable

 Deliverables

List of deliverables.
Set up project homepage Websites, patent fillings, videos etc. 2019-07-25 13:49:19

Take a look to the deliverables list in detail:  detailed list of GLIOMARK deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOMARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOMARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More